Regulus Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative medicines targeting microRNAs, reported its financial results for the first quarter ending March 31, 2025. Regulus reported a net loss of $9.6 million for the quarter, compared to a net loss of $8.5 million for the same period in 2024. The company noted an increase in its research and development expenses to $6.8 million from $6.0 million year-over-year, reflecting costs associated with advancing its clinical and preclinical pipeline. General and administrative expenses also rose to $3.7 million from $2.8 million in the previous year, representing personnel-related and general business operating costs. In terms of cash position, Regulus had $65.4 million in cash, cash equivalents, and short-term investments as of March 31, 2025, with expectations for its cash runway to extend into early 2026. Additionally, the company announced its planned acquisition by Novartis for $7.00 per share in cash, with an additional contingent value right of $7.00 per share upon achieving a regulatory milestone, bringing the total potential equity value to approximately $1.7 billion. This acquisition is expected to complete in the second half of 2025. Regulus is also on track to initiate a Phase 3 single pivotal trial for its drug candidate, farabursen, targeting autosomal dominant polycystic kidney disease (ADPKD) in the third quarter of 2025.